JP2019536810A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536810A5
JP2019536810A5 JP2019530725A JP2019530725A JP2019536810A5 JP 2019536810 A5 JP2019536810 A5 JP 2019536810A5 JP 2019530725 A JP2019530725 A JP 2019530725A JP 2019530725 A JP2019530725 A JP 2019530725A JP 2019536810 A5 JP2019536810 A5 JP 2019536810A5
Authority
JP
Japan
Prior art keywords
benzenesulfonamide
amino
thiazol
fluoro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019530725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536810A (ja
JP7022751B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/033666 external-priority patent/WO2018106284A1/en
Publication of JP2019536810A publication Critical patent/JP2019536810A/ja
Publication of JP2019536810A5 publication Critical patent/JP2019536810A5/ja
Application granted granted Critical
Publication of JP7022751B2 publication Critical patent/JP7022751B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019530725A 2016-12-09 2017-05-19 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 Active JP7022751B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662432169P 2016-12-09 2016-12-09
US62/432,169 2016-12-09
PCT/US2017/033666 WO2018106284A1 (en) 2016-12-09 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents

Publications (3)

Publication Number Publication Date
JP2019536810A JP2019536810A (ja) 2019-12-19
JP2019536810A5 true JP2019536810A5 (https=) 2020-06-25
JP7022751B2 JP7022751B2 (ja) 2022-02-18

Family

ID=62488471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019530725A Active JP7022751B2 (ja) 2016-12-09 2017-05-19 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Country Status (18)

Country Link
US (2) US20180162868A1 (https=)
EP (1) EP3551626B1 (https=)
JP (1) JP7022751B2 (https=)
KR (1) KR20190086772A (https=)
CN (1) CN110325531B (https=)
AU (1) AU2017371674B2 (https=)
BR (1) BR112019011121A2 (https=)
CL (1) CL2019001481A1 (https=)
CO (1) CO2019005552A2 (https=)
ES (1) ES2967410T3 (https=)
IL (1) IL267143A (https=)
MA (1) MA48583A (https=)
MX (1) MX2019006697A (https=)
PH (1) PH12019501074A1 (https=)
RU (1) RU2760303C2 (https=)
SG (2) SG10201912376VA (https=)
TN (1) TN2019000175A1 (https=)
WO (1) WO2018106284A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3458449T3 (pl) 2016-05-20 2025-06-23 Xenon Pharmaceuticals Inc. Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
US10745392B2 (en) * 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
KR20210054510A (ko) * 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
CN111285825B (zh) * 2018-12-10 2023-02-17 中国科学院上海药物研究所 一类苯磺酰胺取代的衍生物,其制法及其用途
CN112125838B (zh) * 2020-08-31 2021-07-27 浙江工业大学 一种三氟甲基化苯胺类化合物及其应用
WO2023028056A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
CN113861130A (zh) * 2021-09-29 2021-12-31 守恒(厦门)医疗科技有限公司 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用
CN113698357A (zh) * 2021-09-29 2021-11-26 守恒(厦门)医疗科技有限公司 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用
US20250034108A1 (en) * 2023-07-07 2025-01-30 Novartis Ag Sodium channel blockers

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
EP0981327B1 (en) 1997-05-07 2002-11-06 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Mek阻害剤を用いる慢性疼痛の治療方法
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP2009513523A (ja) 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
US8202861B2 (en) 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
JP2008524244A (ja) * 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
NZ593074A (en) 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
EP2054385A2 (en) 2006-08-15 2009-05-06 F. Hoffmann-Roche AG Phenyl, pyridine and quinoline derivatives
US7968556B2 (en) 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
US8853250B2 (en) * 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
RU2011103451A (ru) 2008-07-01 2012-08-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
HUE025013T2 (hu) * 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
EP2606051B1 (en) 2010-08-20 2016-10-05 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
JP2014532660A (ja) 2011-10-28 2014-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
RU2014121984A (ru) * 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR102038607B1 (ko) * 2012-10-15 2019-10-30 주식회사 대웅제약 소디움 채널 차단제, 이의 제조방법 및 이의 용도
JP2015535252A (ja) 2012-10-26 2015-12-10 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 電位作動型ナトリウムチャネルにおいて選択的活性を有するn−置換インダゾールスルホンアミド化合物
EP2911668A4 (en) 2012-10-26 2016-07-20 Merck Sharp & Dohme BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS
TW201443025A (zh) * 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) * 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014201173A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
JP6407285B2 (ja) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company RORγ調節因子
UA120353C2 (uk) 2013-09-10 2019-11-25 Хромоселл Корпорейшн Модулятори натрієвого каналу для лікування болю і діабету
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
AU2014370407B2 (en) * 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
WO2016177340A1 (zh) 2015-05-05 2016-11-10 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
US10519147B2 (en) 2015-12-18 2019-12-31 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3484464B1 (en) * 2016-03-22 2020-10-28 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
PL3458449T3 (pl) 2016-05-20 2025-06-23 Xenon Pharmaceuticals Inc. Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne
US10836758B2 (en) * 2016-10-27 2020-11-17 Bristol-Myers Squibb Company Acyl sulfonamide NaV1.7 inhibitors
WO2018093694A1 (en) * 2016-11-17 2018-05-24 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도

Similar Documents

Publication Publication Date Title
JP2019536810A5 (https=)
RU2019120812A (ru) Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
RU2200158C2 (ru) Замещенные изоксазолы, фармацевтические композиции на их основе и способ подавления воспалений
ES2536191T3 (es) Derivados de sulfonamida
JP2004502670A5 (https=)
JP2021515033A5 (https=)
JP2010533158A5 (https=)
JP2021524484A5 (https=)
CN115884810A (zh) 作为il-17调节剂的咪唑并哒嗪
JP2008501673A5 (https=)
RU2017133983A (ru) Бициклические тетрагидротиазепиновые производные, полезные для лечения неопластических и/или инфекционных заболеваний
JP2005513026A5 (https=)
JP2010540452A5 (https=)
RU2014121984A (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
JP2016503009A5 (https=)
CA2439415A1 (en) Cathepsin cysteine protease inhibitors
RU2010125624A (ru) Новые циклические углеводородные соединения для лечения заболеваний
JPWO2020092196A5 (https=)
JP2020516659A5 (https=)
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy
JPWO2021257418A5 (https=)
JP2017509676A5 (https=)
RU2018123714A (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
JP2021528387A5 (https=)
JPWO2021074281A5 (https=)